Sanofi: Depressive Disorder trials

The registry lists 13 Depressive Disorder studies with Sanofi as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 2 2Phase 3 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive DisorderCompletedNCT00432614Phase 3
• A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With DepressionCompletedNCT00429260Phase 3
• An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive DisorderCompletedNCT00415142Phase 3
• An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive DisorderCompletedNCT00361491Phase 2
• An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive DisorderCompletedNCT00358631Phase 2
• A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive DisorderCompletedNCT00345098Phase 3
• A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)CompletedNCT00336713Phase 3
• An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With DepressionCompletedNCT00319709Phase 3
• An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionCompletedNCT00256113Phase 3
• A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With DepressionCompletedNCT00250653Phase 3
• An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionCompletedNCT00250627Phase 3
• An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionCompletedNCT00250614Phase 3
• An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionCompletedNCT00250601Phase 3